New cancer drug LM-2417 enters human testing for Tough-to-Treat tumors
NCT ID NCT06682780
Summary
This early-stage clinical trial is testing a new drug called LM-2417, both alone and combined with other cancer treatments, in people with advanced solid tumors that have stopped responding to standard therapies. The main goals are to find the safest and most effective dose and to understand how the body processes the drug. Researchers will enroll about 320 adults to carefully monitor side effects and see if the treatment helps shrink tumors or slow their growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
FuDan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.